Financial Data and Key Metrics Changes - Revenue for the total company was $569 million, growing 30% year over year, driven by total Omnipod growth of 29% [19][24] - Gross margin was 71.9%, up 240 basis points, primarily due to improved manufacturing and supply chain efficiencies [32][42] - Adjusted operating margin was 16.4% and adjusted EBITDA was 23.5% in the first quarter [33] Business Line Data and Key Metrics Changes - U.S. Omnipod revenue grew 26%, exceeding guidance, with strong demand for Omnipod five [24] - Over 30% of U.S. new customer starts were Type two, indicating successful market penetration [18][63] - International revenue grew 36% above the high end of guidance, driven by strong demand for Omnipod five [29] Market Data and Key Metrics Changes - Estimated global utilization remained stable compared to the prior year, with an annualized retention rate steady in the U.S. and improved slightly internationally [19][20] - The U.S. sales force expansion has increased the number of healthcare providers engaging with Type two patients by over 20% year over year [28][62] Company Strategy and Development Direction - The company aims to expand its market presence in Type one and Type two diabetes, with a focus on innovation and direct-to-consumer strategies [12][14] - The leadership transition is seen as a pivotal moment for driving growth and enhancing operational execution [6][7] - The company plans to leverage its data to improve patient engagement and retention [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing a strong first quarter performance and a robust pipeline of innovation [47][48] - The strategic priorities include advancing innovation, driving growth in U.S. Type one and Type two populations, and expanding internationally [14][40] - Management anticipates continued strong demand trends benefiting from the differentiated Omnipod five platform [38] Other Important Information - The company raised its full-year revenue growth guidance to a range of 19% to 22% [37] - The gross margin guidance for the full year was raised to approximately 71%, despite anticipated tariff impacts [42] - The company has a strong cash position with approximately $1.3 billion in cash and a $500 million credit facility available [35] Q&A Session Summary Question: What excites you about the role and vision for the business? - The new CEO expressed passion for the diabetes space and confidence in the company's unique insulin delivery platform, emphasizing the potential for future value creation [52][54] Question: Will there be a focus on top-line growth at the expense of margin expansion? - The CEO reassured that the business strategy remains intact, with continued focus on double-digit growth and margin improvement [58][60] Question: How is the Type two pump adoption going in the U.S.? - The Type two launch is progressing well, with a significant increase in new customer starts from Type two diabetes [61][63] Question: What are the drivers of strong new customer growth? - The differentiation of Omnipod five and effective direct-to-consumer advertising are key factors driving new customer starts [72][105] Question: What is the outlook for international expansion? - The company plans to launch Omnipod five in the Middle East by early 2026, with ongoing growth in established markets like the U.K. and Germany [91][94]

Financial Performance & Growth - Insulet reported $2.1 billion in revenue for 2024[12] - The company achieved a gross margin of 69.8% in FY 2024, a year-over-year increase of 210 basis points[14] - Insulet's operating margin for FY 2024 was 14.9%, representing a 260 basis points increase year-over-year[14] - The company anticipates revenue growth between 19% and 22% for FY 2025[17] - International Omnipod revenue grew at a CAGR of approximately 17% from 2020 to 2025E, reaching ~$673 million[46] - U S Omnipod revenue grew at a CAGR of approximately 28% from 2020 to 2025E, reaching ~$1.8 billion[43] Omnipod 5 & Market Position - Omnipod is the 1 insulin pump for new pump users in the U S and EU in 2024[12] - Omnipod 5 is the first AID system FDA-cleared for both type 1 and type 2 diabetes in the U S [12] - Omnipod 5 demonstrated a 20%-23% increase in time in range for adults with type 1 and type 2 diabetes, respectively[19] - Approximately 365,000 customers are using Omnipod 5[12]

Exhibit 99.1 Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency ) 1 Raising Full Year Revenue and Gross Margin Guidance ACTON, Mass. - May 8, 2025 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced financial results for the three months ended March 31, 2025. ® "Our first quarter results showcase the strong execution and dedication of the Insulet ...

Core Viewpoint - Wall Street analysts expect Insulet (PODD) to report quarterly earnings of $0.81 per share, reflecting an 11% year-over-year increase, with revenues projected at $541.33 million, a 22.6% increase compared to the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised down by 1.1% in the past 30 days, indicating a reassessment by covering analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Revenue Projections - Analysts estimate 'Revenue- Total Omnipod' at $534.28 million, representing a 23.4% increase year-over-year [5]. - 'Revenue- Drug Delivery' is expected to reach $7.37 million, indicating a decline of 15.3% year-over-year [5]. - 'Revenue- International Omnipod' is projected at $144.78 million, reflecting a 25.6% increase year-over-year [5]. - 'Revenue- U.S. Omnipod' is estimated at $389.50 million, showing a 22.6% increase from the prior-year quarter [6]. Stock Performance - Over the past month, Insulet shares have returned +4.8%, outperforming the Zacks S&P 500 composite's +0.4% change [6]. - Currently, Insulet carries a Zacks Rank 4 (Sell), suggesting potential underperformance in the near future [6].

Insulet (PODD) shares soared 7.2% in the last trading session to close at $264.72. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.7% gain over the past four weeks.Insulet recorded a strong price rise on investors’ optimism surrounding its impending first-quarter 2025 financial results, which is slated to release on May 8 post the closing bell. The Zacks Consensus Estimate for the first quarter revenue suggests a growth of 22.7 ...

Insulet Corporation (PODD) recently made its Omnipod 5 Automated Insulin Delivery (“AID”) system commercially available in Canada for people with type 1 diabetes (ages two years and above). Omnipod 5 is available with Dexcom G6 and G7 continuous glucose monitoring (“CGM”) sensor compatibility. The latest development represents a significant step forward in expanding access to its innovative, tubeless Omnipod 5 AID system for more people globally. PODD Stock’s Likely Trend Following the NewsFollowing the ann ...

Insulet Corporation (PODD) has witnessed strong momentum in the past year. Shares of the company have risen 62.9% compared with 9.9% growth of the industry during the same time frame. The S&P 500 Composite has increased 9.1%.With healthy fundamentals and strong growth opportunities, this Zacks Rank #2 (Buy) company appears to be a solid wealth creator for its investors at the moment.Insulet develops, manufactures and markets the Omnipod System — an innovative, discreet and easy-to-use continuous insulin del ...

Insulet Corporation (PODD) recently made its Omnipod 5 Automated Insulin Delivery (“AID”) System commercially available in Australia. Omnipod 5 is available with Dexcom G6 and G7 continuous glucose monitoring (“CGM”) sensor compatibility. The latest development represents a significant step forward in expanding access to its innovative, tubeless Omnipod 5 AID system for more people globally. PODD Stock’s Likely Trend Following the NewsFollowing the announcement on March 18, PODD’s shares climbed 2% to $265. ...

Insulet Corporation (PODD) announced favorable RADIANT trial clinical data for its Omnipod 5 at the 18th International Conference on Advanced Technologies and Treatments for Diabetes (“ATTD”). Omnipod 5 is the only FDA-cleared, fully disposable pod-based automated insulin delivery ("AID") system. The RADIANT trial results demonstrate Omnipod 5 to be clinically efficient for people living with type 1 diabetes. The conference was held in Amsterdam, Netherlands.PODD Stock’s Likely Trend Following the NewsFollo ...

Company Overview - Insulet Corp (NASDAQ: PODD) operates in the health care sector, specializing in health care equipment, particularly insulin delivery systems like the Omnipod platform [1]. Investment Strategy - The company is of interest to individual investors looking to build financial assets for retirement, with strategies that include both long and short trading, as well as the use of inverse ETFs to capitalize on market declines [1]. Analyst Position - The analyst has a beneficial long position in PODD shares, indicating confidence in the company's future performance [2].